Everything You Want to Know About GLP-1 Weight Loss

Semaglutide is a GLP-1 receptor agonist that activates a single hormonal pathway involved in appetite regulation and blood sugar control. In the landmark STEP 1 clinical trial, patients lost an average of 15 to 17% of body weight over 68 weeks.

Tirzepatide is a dual GIP/GLP-1 receptor agonist that activates two pathways simultaneously. This dual mechanism produces greater appetite suppression. The SURMOUNT-1 trial showed an average of 20 to 22.5% body weight loss, the highest ever recorded in a pharmaceutical weight loss trial.

Both are prescription-only medications prescribed by a licensed medical provider when clinically appropriate. Your provider will recommend the right fit based on your individual health profile, goals, and medical history. Individual results vary and are not guaranteed.

For most eligible patients, the clinical evidence strongly supports GLP-1 therapy as an effective, medically supervised weight loss option. GLP-1 receptor agonists have been studied in large-scale clinical trials involving tens of thousands of patients over multiple years.

Like all prescription medications, GLP-1 therapy carries potential side effects, most commonly gastrointestinal symptoms such as nausea, mild stomach discomfort, and occasional constipation, particularly during dose escalation. These typically subside as your body adjusts.

The decision is made by a licensed medical provider based on your individual health profile. If GLP-1 therapy is not clinically appropriate for you, your provider will tell you. Open Water Rx does not prescribe to patients for whom the therapy is not indicated.

GLP-1 therapy is not appropriate for everyone. A licensed medical provider will review your full health history before any prescription is issued. GLP-1 medications are generally not prescribed for patients with:

- A personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) - A history of pancreatitis - Certain gastrointestinal conditions - Pregnancy or plans to become pregnant - Certain other medical conditions or medication interactions

This is not a complete list. Your provider will assess your full health profile and make an independent clinical determination. If GLP-1 therapy is not right for you, your provider will explain why and may suggest alternatives.

Semaglutide is a GLP-1 receptor agonist that mimics a natural gut hormone called glucagon-like peptide-1. After you eat, GLP-1 is released and signals your brain that you are full, slows the rate at which your stomach empties, and helps regulate blood sugar.

Semaglutide amplifies these signals significantly and sustains them throughout the week with a single weekly injection. The result is a meaningful and sustained reduction in appetite, leading to lower caloric intake without the constant hunger that makes traditional dieting so difficult.

In the landmark STEP 1 clinical trial published in the New England Journal of Medicine, patients on semaglutide 2.4mg lost an average of 15 to 17% of body weight over 68 weeks. Individual results vary and are not guaranteed.

Most patients notice the first effects of semaglutide within 1 to 2 weeks of starting therapy, typically as a subtle reduction in appetite or earlier feelings of fullness at meals.

Meaningful weight loss usually begins within 4 to 8 weeks. The full effect builds gradually as the dose is titrated upward over several months according to your provider's schedule.

Timeline overview: - Week 1 to 2: Subtle appetite reduction, possible mild nausea - Week 4 to 8: Noticeable weight loss begins for most patients - Month 3 to 6: Continued weight loss as dose reaches therapeutic levels - Month 6 to 12: Sustained weight loss, often stabilizing as dose is optimized

Individual response varies. Your provider will monitor your progress and adjust your plan accordingly.

Research consistently shows that weight tends to return when semaglutide is discontinued. In the STEP 1 extension study, patients who stopped semaglutide regained approximately two-thirds of their lost weight within one year of stopping.

This is not a failure of willpower. Semaglutide works by actively suppressing appetite signals. When the medication is stopped, those signals return to their previous levels.

For many patients, semaglutide is most effective as a long-term program rather than a short-term intervention. Your licensed medical provider will discuss the appropriate duration of treatment based on your individual health profile and goals. If you are considering stopping, always consult your provider first rather than stopping abruptly.

Rapid weight loss on semaglutide, as with any significant caloric deficit, can include some loss of lean muscle mass alongside fat loss. This is a known consideration with GLP-1 therapy.

To minimize muscle loss while on semaglutide, most providers recommend: - Prioritizing adequate protein intake at every meal, even when appetite is significantly reduced - Incorporating resistance exercise or strength training into your routine - Avoiding excessively low caloric intake

The clinical significance of muscle loss on semaglutide is still being studied. Current evidence suggests that the cardiovascular and metabolic benefits of the fat loss achieved with semaglutide outweigh the muscle loss concern for most eligible patients. Your provider will give you personalized guidance.

No. Compounded semaglutide uses the same active pharmaceutical ingredient (API) as Ozempic and Wegovy, but it is not the same product and is not interchangeable with any FDA-approved drug.

Ozempic and Wegovy are FDA-approved finished drug products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed, FDA-registered compounding pharmacy for an individual patient when a licensed medical provider determines it is clinically appropriate, for example, when a specific dosage, formulation, or delivery method not available in the commercial product is needed.

Compounded semaglutide is not FDA-approved as a finished drug product and has not been evaluated by the FDA for safety, efficacy, or quality in the same manner as commercially manufactured drugs. Open Water Rx works exclusively with pharmacies that use the base API, not salt derivatives such as semaglutide sodium or semaglutide acetate.

Semaglutide for weight loss is administered as a once-weekly subcutaneous injection. The dose is gradually increased over several months to minimize side effects and allow your body to adjust.

A typical titration schedule starts at a low dose (commonly 0.25mg per week) and increases incrementally every 4 weeks until reaching the target therapeutic dose. The specific schedule is determined by your licensed medical provider based on your individual health profile, tolerance, and clinical response.

Do not adjust your dose without consulting your provider. Rushing the titration schedule is one of the most common causes of significant gastrointestinal side effects. Your provider will guide you through each step.

Semaglutide is administered as a once-weekly subcutaneous injection, meaning it is injected just under the skin rather than into a muscle or vein. Common injection sites include the abdomen, upper thigh, or upper arm.

Your prescribing provider and dispensing pharmacy will provide detailed injection instructions specific to your medication formulation. General best practices include: - Rotating injection sites each week to avoid skin irritation - Injecting at the same time each week for consistency - Allowing the medication to reach room temperature before injecting if refrigerated - Using a new needle for each injection

Most patients find the injection straightforward after the first few times. If you have concerns about self-injection, discuss them with your provider.

Tirzepatide is a GLP-1 receptor agonist, so it is technically a type of GLP-1 medication. The key distinction is that tirzepatide is a dual agonist: it activates both the GLP-1 (glucagon-like peptide-1) receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously.

Standard GLP-1 medications like semaglutide activate only the GLP-1 receptor. Tirzepatide's dual mechanism produces stronger appetite suppression and greater average weight loss. In the SURMOUNT-1 trial, tirzepatide produced an average of 20 to 22.5% body weight loss, compared to 15 to 17% for semaglutide in the STEP 1 trial.

When people refer to 'GLP-1 medications' as a category, they typically mean the entire class including both semaglutide and tirzepatide. Tirzepatide is the more advanced dual-receptor option within that class. Individual results vary and are not guaranteed.

Tirzepatide is highly effective, but it does have drawbacks worth understanding before starting:

- Cost: Tirzepatide plans start at $339/month through Open Water Rx, higher than semaglutide plans starting at $249/month, due to the more complex active pharmaceutical ingredient and manufacturing process. - Gastrointestinal side effects: Nausea, constipation, stomach discomfort, and occasional diarrhea are common, particularly during dose escalation. These are similar to semaglutide but may be more pronounced for some patients given the dual-receptor mechanism. - Injection requirement: Like semaglutide, tirzepatide is a weekly subcutaneous injection. - Muscle mass: Rapid weight loss on tirzepatide can include some lean muscle loss. Adequate protein intake and resistance exercise are recommended. - Ongoing commitment: Weight tends to return when tirzepatide is discontinued without lifestyle changes in place. - Prescription required: Tirzepatide is a prescription-only medication. A licensed medical provider must determine it is clinically appropriate for you.

Your provider will review all relevant risks and benefits with you during your evaluation.

Both tirzepatide and semaglutide have been studied in large-scale clinical trials and have well-characterized safety profiles. Neither is definitively 'safer' than the other in a general sense. The safety comparison depends on the individual patient.

Both medications share a similar side effect profile, primarily gastrointestinal symptoms such as nausea, constipation, and stomach discomfort. Both carry the same class-level contraindications, including a personal or family history of medullary thyroid carcinoma or MEN 2.

Tirzepatide's dual GIP/GLP-1 mechanism is newer, and long-term data beyond 2 to 3 years is still accumulating compared to the longer track record of GLP-1 monotherapy. However, the clinical trial data available to date does not indicate that one is meaningfully safer than the other for the general eligible population.

Your licensed medical provider will assess your individual health profile and recommend the medication that is most appropriate for you specifically. This is general information, not medical advice.

Based on published clinical trial data, most tirzepatide patients begin to see meaningful weight loss within 4 to 8 weeks of starting therapy. Losing 20 pounds typically takes 2 to 4 months for many patients, though this varies significantly based on starting weight, dosage, adherence, diet, and activity level.

Tirzepatide tends to produce faster and greater weight loss than semaglutide. In the SURMOUNT-1 trial, patients on the highest dose lost an average of 22.5% of body weight over 72 weeks. For a patient starting at 220 pounds, that represents approximately 49 pounds.

Individual results vary and are not guaranteed. GLP-1 therapy is not a quick fix. It works best as part of a sustained, medically supervised program with appropriate nutrition and activity.

While on tirzepatide, most providers recommend avoiding or limiting the following:

- High-fat, greasy, or fried foods: These worsen nausea and gastrointestinal side effects, which can be more pronounced with tirzepatide's dual-receptor mechanism - Large meals: Tirzepatide significantly slows gastric emptying; large portions can cause substantial discomfort - Alcohol: Can worsen nausea, affect blood sugar regulation, and add empty calories that work against your weight loss goals - Skipping meals entirely: Adequate nutrition is important for preserving lean muscle mass, even when appetite is significantly reduced - Stopping tirzepatide abruptly without provider guidance: Discuss any changes to your dosing schedule with your provider - Rushing dose escalation: The titration schedule exists to minimize side effects. Do not increase your dose faster than prescribed.

Your licensed medical provider will give you personalized guidance. This is general information, not medical advice.

Tirzepatide works through multiple mechanisms, not just appetite suppression.

Appetite suppression is the primary driver: tirzepatide activates GLP-1 and GIP receptors in the brain and gut, significantly reducing hunger signals and increasing feelings of fullness. This leads to a meaningful reduction in caloric intake.

Beyond appetite suppression, tirzepatide also: - Slows gastric emptying, which prolongs feelings of fullness after meals - Improves insulin sensitivity and glucose metabolism, which affects how the body processes and stores energy - May have direct effects on fat cell metabolism through GIP receptor activation, though the full mechanism is still being studied

The net result is that the body enters a sustained caloric deficit, which drives fat loss. Tirzepatide does not directly 'burn' fat in the way exercise does, but the metabolic and appetite effects it produces create the conditions for significant fat loss. Individual results vary and are not guaranteed.

Tirzepatide produces faster and greater weight loss than most other interventions because of its dual mechanism. By activating both GLP-1 and GIP receptors simultaneously, it creates a stronger and more sustained reduction in appetite than GLP-1 monotherapy alone.

Many patients on tirzepatide report a dramatic reduction in food noise, the constant background thoughts about food and hunger that most people experience. When appetite is significantly suppressed, caloric intake drops substantially, often without feeling deprived.

Additionally, tirzepatide improves insulin sensitivity and glucose metabolism, which affects how efficiently the body stores and uses energy.

If you feel you are losing weight very rapidly, it is important to: - Ensure you are still eating adequate protein to preserve lean muscle mass - Stay well-hydrated - Communicate with your provider through secure messaging

Rapid weight loss is generally expected on tirzepatide, but your provider should be aware of your progress to ensure your dosing and nutrition plan remain appropriate. Individual results vary.

Most patients notice the first effects of tirzepatide within the first 1 to 2 weeks of starting therapy, typically as a reduction in appetite or earlier feelings of fullness at meals.

Meaningful weight loss usually begins within 4 to 8 weeks. The full effect of tirzepatide builds gradually as the dose is titrated upward over several months according to your provider's schedule.

Timeline overview: - Week 1 to 2: Subtle appetite reduction, possible mild nausea - Week 4 to 8: Noticeable weight loss begins for most patients - Month 3 to 6: Significant weight loss as dose reaches therapeutic levels - Month 6 to 12: Continued weight loss, often accelerating as dose is optimized

Individual response varies. Some patients respond strongly at lower doses; others require higher doses to see significant effects. Your provider will monitor your progress and adjust your plan accordingly.

The most commonly reported downsides of GLP-1 therapy include:

- Gastrointestinal side effects: nausea, stomach discomfort, constipation, or diarrhea, especially during dose escalation. These typically improve as your body adjusts. - Injection requirement: GLP-1 medications are administered as a weekly subcutaneous injection. Some patients find this uncomfortable initially. - Cost: Without insurance coverage, GLP-1 therapy requires an ongoing monthly investment. Open Water Rx plans start at $249/month for semaglutide and $339/month for tirzepatide, all-inclusive. - Muscle loss risk: Rapid weight loss can include some lean muscle mass loss. Your provider may recommend protein intake and resistance exercise to mitigate this. - Ongoing commitment: GLP-1 therapy works best as part of a sustained program. Weight may return if medication is discontinued without lifestyle changes in place.

Your provider will discuss all relevant risks and benefits with you during your evaluation.

The most commonly reported side effect of GLP-1 medications is nausea, particularly during the initial weeks of treatment and when the dose is increased. In clinical trials, nausea was reported by a significant portion of patients but was generally mild to moderate and temporary.

Nausea typically peaks during dose escalation and subsides as your body adjusts to the medication. Eating smaller meals, avoiding high-fat or spicy foods, and staying hydrated can help manage it.

Other common gastrointestinal side effects include constipation, mild stomach discomfort, and occasional diarrhea. Serious side effects are rare but possible. Your licensed medical provider will review all relevant risks with you before prescribing.

The timeline varies significantly by individual. Based on published clinical trial data, most patients begin to see meaningful weight loss within 4 to 8 weeks of starting GLP-1 therapy. Losing 20 pounds typically takes 3 to 6 months for many patients, though this depends on your starting weight, dosage, adherence, diet, and activity level.

In the STEP 1 trial, patients lost an average of 15 to 17% of body weight over 68 weeks on semaglutide. In the SURMOUNT-1 trial, tirzepatide patients lost an average of 20 to 22.5% over a similar period.

Individual results vary and are not guaranteed. GLP-1 therapy is not a quick fix. It works best as part of a sustained, medically supervised program.

On your first day of GLP-1 therapy, most patients do not feel dramatic effects immediately. The medication takes time to build up in your system.

What you may notice in the first few days: - Mild nausea or stomach awareness, particularly after eating - Slightly reduced appetite or earlier feelings of fullness - Occasional mild fatigue as your body adjusts

What you likely will not notice yet: - Significant weight loss (this takes weeks) - Strong appetite suppression (this builds gradually)

Your provider will give you a titration schedule, typically starting at a low dose and increasing gradually over several weeks to minimize side effects. Follow your dosing instructions carefully and reach out to your provider through secure messaging if you have concerns.

Patient experiences vary, but the most commonly reported feelings after the first injection include:

- Mild nausea or stomach awareness, usually appearing within a few hours and lasting a day or two - A subtle reduction in appetite, often noticed at the next meal - Occasional mild fatigue or lightheadedness - Some patients report feeling little to nothing after the first dose, which is normal at the starting dose

The first injection is typically at the lowest dose in your titration schedule, so effects are often subtle. Side effects tend to be most noticeable during dose increases. Most patients find that symptoms improve significantly after the first 2 to 4 weeks as their body adjusts.

Fat loss patterns on GLP-1 therapy follow the same general principles as other forms of weight loss: the body tends to lose fat from the abdomen and visceral fat stores first, which is actually the most clinically significant type of fat loss from a health standpoint.

Visceral fat, the fat stored around internal organs, is metabolically active and associated with increased cardiovascular and metabolic risk. Reducing it has meaningful health benefits beyond aesthetics.

Subcutaneous fat (the fat you can pinch under the skin) and fat in specific areas like the face, arms, and legs tends to reduce more gradually. Individual fat distribution patterns vary significantly based on genetics, sex, age, and other factors. Results are not guaranteed and vary by individual.

GLP-1 therapy is designed for long-term use in eligible patients. Clinical trials have studied patients on GLP-1 medications for up to 2 years, and ongoing research continues to evaluate longer-term use.

For many patients, GLP-1 therapy is most effective as a sustained program rather than a short-term intervention. Research has shown that weight tends to return when GLP-1 medications are discontinued without lifestyle changes in place.

Your licensed medical provider will assess your ongoing eligibility and clinical appropriateness at each follow-up. The duration of your program is determined by your provider based on your individual health profile, goals, and response to treatment. There is no fixed maximum duration for clinically appropriate patients.

Patients who have been through GLP-1 therapy commonly share these insights:

- Start slow and be patient. The medication works gradually. The titration schedule exists for a reason. - Nausea is real but temporary. It typically peaks during dose increases and fades as your body adjusts. Eating smaller, lower-fat meals helps. - Protein matters. GLP-1 therapy reduces overall appetite, which can make it easy to under-eat protein. Prioritizing protein helps preserve lean muscle mass. - Hydration is important. Reduced appetite can also mean reduced fluid intake. Drink water consistently throughout the day. - The appetite suppression is different from willpower. Many patients describe it as simply not thinking about food the way they used to. This is the medication working. - Results take time. Meaningful weight loss typically begins within 4 to 8 weeks. Comparing week-to-week can be discouraging. Focus on the trend over months. - Your provider is your partner. Use the secure messaging system. Ask questions. Report side effects. This is a medically supervised program.

While on GLP-1 therapy, most providers recommend avoiding or limiting:

- High-fat, greasy, or fried foods: These can worsen nausea and gastrointestinal side effects - Large meals: GLP-1 slows gastric emptying; eating large portions can cause significant discomfort - Alcohol: Can worsen nausea and may interact with blood sugar regulation - Skipping meals entirely: While appetite is reduced, adequate nutrition is important for preserving muscle mass and energy - Stopping the medication abruptly without provider guidance: Discuss any changes to your dosing schedule with your provider

Your licensed medical provider will give you personalized guidance based on your health profile. This is general information, not medical advice.

There is no strict requirement to eat before your GLP-1 injection, as it is a weekly subcutaneous injection rather than an oral medication. However, many patients find that:

- Eating a light, low-fat meal or snack before injecting can help reduce nausea in the hours following the injection - Avoiding heavy, greasy, or high-fat meals around injection time is helpful - Staying well-hydrated before and after your injection supports overall comfort

Your provider will give you specific guidance on injection timing and technique. If you experience significant nausea after injections, discuss it with your provider. Dosage adjustments or timing changes may help.

Most patients who feel their best on GLP-1 therapy follow a few consistent practices:

- Prioritize protein at every meal. Aim for adequate protein intake even when appetite is reduced. This preserves lean muscle and supports energy. - Eat smaller, more frequent meals. GLP-1 slows digestion; smaller portions are more comfortable and reduce nausea. - Stay hydrated. Reduced appetite can mean reduced fluid intake. Drink water consistently throughout the day. - Move your body. Light to moderate exercise, even walking, supports weight loss, mood, and muscle preservation. - Follow your titration schedule. Do not rush dose increases. The gradual schedule exists to minimize side effects. - Communicate with your provider. Use secure messaging to report side effects or ask questions. Your provider can adjust your plan. - Be patient with the process. GLP-1 therapy is a sustained program. The best results come from consistency over months, not weeks.